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ABSTRACT 
 
Pulmonary artery capacitance (PVCAP) is the ability of the pulmonary artery to 
accept a volume of blood at a given pressure. Traditionally measured invasively 
with heart catheterization; PaCAP may be estimated non-invasively through the 
measurement of end-tidal CO2 (PETCO2) and stroke volume (SV), known as gas-
exchange capacitance (GXCAP) where a higher capacitance means improved 
pulmonary vasodilation. The degree of pulmonary vascular dysfunction at rest 
and during exercise remains unclear in patients with cystic fibrosis (CF). 
PURPOSE: To determine the effects of exercise on GXCAP in patients with CF, 
when compared to healthy subjects. METHODS: 19 patients with CF 
(age=22±2yrs, BMI=23±1kg/m2, VO2=56±6%pred., FVC=83±5%pred., 
FEV1=72±6%pred., FEV1/FVC=0.72±0.02) and 17 healthy subjects 
(age=22±1yrs, BMI=23±1kg/m2, VO2=81±5%pred., FVC=93±3%pred., 
FEV1=89±2%pred., FEV1/FVC=0.81±0.02) were recruited for this study. Exercise 
testing was performed on a cycle ergometer. PETCO2 was assessed using a 
metabolic cart, SV was assessed using the acetylene rebreathe technique and 
GXCAP was calculated from the product of PETCO2 and SV.  RESULTS: At rest, SV 
and GXCAP were higher in healthy subjects when compared to CF (SV=72±6 vs. 
54±5ml, GXCAP=22±2 vs. 17±2, for healthy and CF, respectively. PETCO2 
remained unchanged between healthy and CF subjects (PETCO2 30±1 and 30±1 
respectively). Healthy subjects exercised at a higher absolute intensity, but 
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intensity expressed as a percentage of max was similar between healthy and CF 
(watts=159±10 vs. 102±8, watts/max watts=96±3 vs. 95±5% for healthy and CF, 
respectively). At peak exercise, SV and GXCAP increased in both healthy and CF 
but remained higher in healthy subjects when compared to CF (SV=108±5 vs. 
84±6ml, GXCAP=40±3 vs. 29±2, for healthy and CF, respectively, p<0.05). When 
matched for a workload designed to match for SV, there was no difference in 
percent of max watts (%MaxW=63±4 vs. 66±5W), Q (11±1 vs. 13±1L/min), or SV 
(89±4 vs. 90±4ml/beat). When matched, the previous difference in GXCAP in 
healthy and CF was abolished (GXCAP=32±2 vs. 32±2mL/BEAT ∙ min). 
CONCLUSION: Gas exchange capacitance is lower in patients with CF at rest 
and through peak exercise. However, when matched for SV and workload, 
GXCAP was statistically similar between healthy and CF. This lower GXCAP is likely 
due to lower SV at rest and with peak exercise in CF patients, when compared to 
healthy subjects. Therefore, these findings suggest that there is no evidence of 
pulmonary vasculature dysfunction in these CF patients. Future, more invasive 
studies are warranted to confirm the lack of difference in pulmonary vascular 
function in patients with CF. 
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CHAPTER 1. INTRODUCTION 
 
 
 
 
 
 
 
 
 
  2 
Cystic Fibrosis (CF) is the most common autosomal recessive genetic 
disorder affecting 1 in 2,500 births among Caucasians. Cystic fibrosis is 
characterized by altered ion regulation throughout the body which manifests as 
chronic lung infection, exacerbations of the pulmonary tree, and death from lung 
disease, leading to the majority of the research being directed towards the 
pulmonary system. With the development of new pharmacotherapies allowing 
subjects to live longer into adulthood, a shift is warranted from this pulmonary-
specific focus on mortality to multisystem research and clinical practice that 
includes the cardiac and vascular systems. This shifted focus should initially be 
set on potential co-morbidities, most notably cardiovascular dysfunction 
associated with potential central and peripheral hemodynamic dysfunction. 
 
Here is encompassed a complete literature review, as well as background, 
methodology, results, discussion, and a conclusion surrounding the proposed 
study are detailed in the following chapters. Please see the overview below: 
 
Chapter two summarizes the current literature related to cardiovascular 
function and central hemodynamics in CF. A brief overview of CF, the associated 
changes in the pulmonary vasculature, the consequences of those changes on 
the heart and validated techniques for assessment. Also, in chapter two, the 
parallels in and differences between cardiovascular function and central 
hemodynamics between healthy and diseased populations will also be 
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discussed. Additionally, specific aims and hypotheses of the present study will be 
clearly stated.  
 
Chapter three summarizes the methodology of this study including data 
collection and measurement techniques, anthropometric assessment, 
measurement of pulmonary function, gas exchange, and description of the 
equations used within the study. Chapter three also details the statistical 
analyses utilized in this study. 
 
Chapter four contains detailed findings of this study. In this chapter we 
examine differences between controls and CF subjects in the study population 
regarding anthropometric and pulmonary function at rest. Further, changes in 
cardiac function and estimates of pulmonary capacitance with exercise are 
described, as well as differences between these two pertinent variables at rest 
and peak exercise, between healthy and CF. 
 
Chapter five summarizes and discusses the implications of the study 
findings in relation to the existing literature. Initial results as well as subsequent 
matching of study groups are discussed. Further, discussion of physiologic 
differences between healthy and CF subjects are also reviewed. 
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Chapter six offers conclusions of the resulting study. Additionally, in 
chapter six, the necessity and future direction of research in cardiovascular 
function and central hemodynamics in CF will be reviewed. 
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CHAPTER 2. REVIEW OF LITERATURE 
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Cystic Fibrosis 
 
Cystic fibrosis (CF) was first described by Anderson in 1938 through the 
recognition that these patients presented with digestive and nutritional 
disturbances, infections of the respiratory tract, as well as postmortem lesions of 
the pancreas and respiratory system (1, 2). Cystic fibrosis is now known to be an 
autosomal-recessive disease affecting one in 2,500 births making it the most 
common life shortening inherited genetic disorder among Caucasian individuals 
(3, 4, 5). There are roughly 30,000 people in the United States (US) living with 
CF and 70,000 cases worldwide. Around 1000 new cases of CF are diagnosed 
each year in the US alone, with 75% of those patients being diagnosed by age 
two (6). Cystic fibrosis is characterized by chronic disease progression and 
multisystem involvement. Although multiple organ systems are affected by CF, 
pulmonary dysfunction receives the greatest focus as CF patients continue to die 
primarily from lung disease. Despite this focus on the pulmonary system, CF 
affects several organ systems including the gastrointestinal, immune, endocrine, 
reproductive, and musculoskeletal (3, 7). 
 
Interestingly, at present, nearly half of the CF population is 18 years of 
age or older, which may be attributed to more widespread use of carrier 
screening (6, 8, 9), improved drug delivery, and improved pharmacotherapy that 
targets specific genetic mutations of the cystic fibrosis transmembrane 
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conductance regulator (CFTR). There are more than 1800 known mutations in 
CFTR that cause CF, although widespread genetic testing screens for the most 
common, the Delta-F508 (ΔF508) mutation. The mutations in the gene that 
encodes for CFTR range from those that are common to some mutations that 
affect only a few people worldwide; this is important because some mutations are 
associated with a wide range of symptoms leading to variation in disease 
severity, treatment options, and survival (8, 9).   
 
The CFTR is a protein anion channel that participates in the fluctuation of 
electrolytes and fluid movement across mucosal surfaces (8, 10). Specifically, 
CFTR has two primary functions that are lost or reduced in patients with CF; (1) 
Cl- secretion to the apical portion of epithelial cells, and (2) inhibition of Na+ 
reabsorption into the cell through epithelial Na+ channels (ENaC). Due to this 
loss of normal ion regulation, CF patients have hyperapsorption of NaCl and, 
therefore, fluid shifts away from the apical portion of cells. Functional CFTR is 
critical at the epithelial surface not only in the respiratory tract but the 
gastrointestinal tract as well in the exocrine gland ducts (8, 10). It is also 
important to note that the CFTR protein is also expressed in the cardiac and 
vascular smooth muscle tissue and may play an important role in cardiac 
contraction and vascular function (11).  
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The pulmonary manifestation of CF is noted by the production of thick 
mucus (due to the loss of airways surface liquid from NaCl hyperabsorption) 
leading to the obstruction of the airways from bronchial trunk to alveoli; 
secondary to this mucus build-up is chronic inflammatory reaction and pulmonary 
multiresistant bacterial infections (4, 12). Most serious of these bacterial 
colonization’s is Pseudomonas aeruginosa or Stenotrophomonas maltophilia 
which account for roughly one to two hospitalizations per year and represents a 
large burden among CF patients (13). The aforementioned chronic inflammation 
over time leads to progressive remodeling of the pulmonary tissue, 
bronchiectasis, and parenchymal fibrosis (4, 14). This cycle of chronic 
inflammation, infection and hospitalization continues throughout the life of a 
patient battling CF. The progressive destruction of the lung tissue in CF leads to 
one of two outcomes: lung transplantation or eventual death. The life expectancy 
of patients with CF is 37.5 years but has the promise of growing with each new 
marked therapeutic development (11). 
 
Increased longevity in CF has warranted increased focus on extra-
pulmonary complications and co-morbidities. A variety of systemic complications 
including gastrointestinal, immune, endocrine musculoskeletal and 
cardiovascular have been noted (7,15). Issues explicit to the cardiac systems 
and pulmonary vasculature have been given some, albeit minimal, attention 
compared to issues of the pulmonary trunk in CF.  Because the heart and lungs 
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lie in series, pulmonary hemodynamics are a critical component in the 
determination of right ventricular performance and overall cardiac health (16, 17). 
Additionally, adult patients with mild to moderate CF severity exhibit evidence of 
systemic large arterial circulation abnormalities (12, 18). Vasculature dysfunction 
causes an increase in arterial stiffness, seen even in children with CF, and 
vasoconstriction of the pulmonary vasculature. Pulmonary vasoconstriction in CF 
is likely initiated by chronic systemic hypoxia that is the result of impaired 
ventilation and gas exchange (1, 19, 20). 
 
The general mechanism of hypoxic pulmonary vasoconstriction in CF is 
largely unknown although the phenomenon was first described by Liljestran in 
1946 (21, 22). It is understood, however, that pressure is increased within the 
lung in an effort to attenuate the non-uniform distribution of blood flow and 
inspired air within the pulmonary tree to better match for ventilation and perfusion 
(19, 21, 23).To optimize ventilation to perfusion in instances of alveoli becoming 
hyperinflated, and/or hypo-inflated in poorly ventilated portions, pulmonary 
vasoconstriction causes blood to shunt away from the poorly-ventilated areas to 
well-ventilated areas (21, 23). This is normal in the healthy lung with 
environmental hypoxic conditions such as ascending to high altitude; however 
when the cause is pathophysiologic, and continual, as in chronic obstructive 
pulmonary disease (COPD), or in CF, stress on the pulmonary vascular system, 
including pulmonary hypertension (PH) and pulmonary vascular remodeling 
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emerge (24, 25). This chronic pulmonary vasoconstriction or PH occurs primarily 
in the smaller pulmonary blood vessels causing a remodeling of the peripheral 
pulmonary trunk (18). This remodeling includes masculinization of the smooth 
muscle and progressive fibrosis of the intima of the pulmonary arterioles. (21). 
However in contrast to the arterial system this remodeling does not seem to 
occur within the venous pulmonary vascular tree (1). Although the general 
mechanism for pulmonary vascular dysfunction has been described in several 
disease states (COPD, heart failure (HF), etc.) this has been poorly 
characterized in patients with CF. 
 
Pulmonary Hypertension in CF 
 
Pulmonary hypertension has been defined as a mean pulmonary artery 
pressure of greater than 25 mm Hg as assessed via invasive right heart 
catheterization. In CF, PH is associated with advanced lung disease and 
negative clinical outcomes (3). Pulmonary hypertension has been recognized in 
the natural progression and development of CF since Anderson first described it 
in 1938, but this co-morbidity remains relatively unstudied (26). Pulmonary 
hypertension has been observed in children with CF as well, with an incidence of 
nearly 70% having been reported (1). Pathology of vasoconstriction within the 
pulmonary trunk is due not only to hypoxia but is confounded by the destruction 
and subsequent vascular remodeling, increasing vascular resistance and, 
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ultimately irreversible PH (22, 27, 28). The prevalence of PH in CF ranged from 
26 up to 63% in previous studies, however the clinical implications of PH from 
young, stable, CF as well as end-stage CF patients awaiting lung transplantation 
has not been yet elucidated (3, 12, 16, 27). Previous work has demonstrated that 
progressive respiratory failure and PH will lead to eventual right HF in other 
disease states that may have similarities to CF (3, 13, 29). As previously 
mentioned the heart and lungs lie in series and are subjugated to similar 
pressures within the thoracic cavity (17). As resistance increases within the lung, 
the afterload the heart needs to overcome to maintain stroke volume (SV) meets 
increased resistance, thus increasing the work of the heart leading to an 
enlargement of the right ventricle (30). This enlargement of the ventricle is due to 
increasing pressure in the lungs. As early as 1988 Burghuber and associates 
indicated preclinical geometric remodeling and ventricular dysfunction in children 
with CF (30). In this same population, decreased right ventricular ejection fraction 
(EF) was also apparent. However, right ventricular EF is highly dependent on 
afterload as had been previously shown in COPD and the authors questioned the 
validity of the measure in assessing right ventricular contractility, let alone 
function (25, 30). 
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Cardiopulmonary Hemodynamic Dysfunction in CF 
 
Regardless of increased pulmonary pressures and vascular stiffening, the 
severity of cardiac dysfunction in CF has had varied findings. Cardiac output (Q) 
has been reported previously as normal at rest as well as during exercise. More 
recently, however, it has been shown that SV and Q may be lower during 
increasing exercise intensity in CF (21, 31, 32). These conflicting findings are 
due to several factors such as the modality and intensity of the exercise as well 
as techniques used for assessing cardiac variables. Adult CF patients with mild 
to moderate severity show evidence of abnormalities of large arterial circulation 
(18).  Concurrently there is an abnormal central hemodynamic response 
apparent in CF patients during exercise which is expressed by greater pressure 
within the pulmonary circulation, when compared to age, gender, and BMI 
matched controls (18). It has also been shown previously that CF patients with 
increased mean pulmonary artery pressure trended towards worse survival, 
similar results were also observed in those patients with decreased EF (3). It has 
been suggested that patients with CF exhibit a deterioration of pulmonary 
hemodynamics in the end-stage of the disease (16). At this end-stage of CF it is 
far more likely that several compounding factors are present causing 
parenchymal destruction, obstruction, and fibrosis to affect the pulmonary 
circulation (16). Dysfunction in central hemodynamics has been associated with 
low life expectancy and increased risk of mortality (16, 26). Studies assessing 
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central hemodynamic impairment are varied in disease and severity suggesting 
multisystem involvement and multifactorial control (16). Prevalence of this 
ventricular dysfunction in CF and advanced lung disease is controversial being 
shown to be high in some studies and low in others (3, 33). These findings have 
been confirmed in younger patients, suggesting abnormal early vascular aging 
even in the setting of normal peripheral blood pressure and may constitute 
important clinical implications in cardiovascular health as longevity increases in 
CF (29). Previous work also suggests premature or accelerated vascular aging of 
the large artery hemodynamics in CF approximately ten years that of their 
chronologic age. Premature vascular aging has been described previously as the 
increased stiffening of the central arterial circulation to that of their aged and sex-
matched healthy controls.  The premature aging demonstrated in these studies 
could not be explained by increased blood pressure, physical activity level, and 
smoking (11, 13, 29, 34). Hemodynamic dysfunction contributes to 
extrapulmonary complications that persist into the adult stage of the disease and 
involves the heart, in addition to the pulmonary vasculature (29).   
 
Assessment of Cardiopulmonary Vascular Function 
 
There are several techniques available for assessing cardiovascular 
hemodynamics and vascular function, in-vivo. Methods range from very reliable 
to questionable and expensive to cost effective as well as invasive to non-
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invasive. Like most measures of organ system function, measures of 
cardiovascular hemodynamics in humans have their faults and strong suits. Here 
we discuss three techniques for assessing Q: the direct Fick method, 
thermodilution, and acetylene rebreathe. The gold standard for assessing Q is 
the direct Fick method where the quotient of oxygen uptake (VO2) and the 
difference of the arterial and mixed venous oxygen content are used to calculate 
Q (12, 17, 32, 35). This technique is used sparingly in clinical practice due to the 
specialty of measuring oxygen uptake and the invasive nature (requirement of 
arterial and venous blood sampling) of pulmonary artery catheterization. In the 
clinical setting the thermodilution technique has been used extensively. 
Thermodilution is performed by injecting ice-cold isotonic saline through the 
proximal right atrial lumen; the difference in temperature from is then calculated. 
This requires a thermistor at the end of the catheter and one in a distal location 
(35). Thermodilution has been shown to be accurate in healthy subjects as well 
as patients with cardiovascular disease. Although the accuracy of the 
thermodilution method is suspect in subjects with low Q or severe tricuspid 
regurgitation both of which present themselves in patients with severe PH (32, 
35). Acetylene rebreathe technique has been used widely as a reliable non-
invasive determinate of Q. Acetylene (C2H2) is an inert, non-physiologic gas 
giving it a low solubility in tissue but a high affinity within the blood. When 
inhaled, the gas is taken up by the pulmonary capillary blood stream at a rate 
proportional to the volume within the pulmonary system (35, 36). As the 
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pulmonary system receives nearly all of the Q the acetylene rebreathe technique 
has been shown to be accurate in estimating Q and SV in animals and humans 
at rest and during exercise (17, 35). 
 
The most accurate method for the assessment of cardiac function and 
pulmonary vascular pressures is cardiac catheterization. During the 
catheterization of the heart a catheter is advanced through the right internal 
jugular vein and into the right side of the heart by way of the superior vena cava. 
The indwelling catheter is then wedged in the pulmonary artery under 
fluoroscopic guidance (17, 32, 37). The placement allows for several metrics to 
be directly measured: systolic, diastolic and mean arterial pressure as well as the 
mean pulmonary artery pressure and pulmonary artery wedge pressure (which is 
important in the assessment of PH. Other measures obtained during cardiac 
catheterization are mixed-venous blood gasses, the aforementioned Q, and SV. 
From these measures peripheral vascular resistance can be assessed as well as 
pulmonary capacitance (PVCAP). Pulmonary capacitance is a measure of the 
pulmonary arteries ability to distend to accept a volume of blood under a given 
pressure (17, 38). This measure of PVCAP may be an important in the 
assessment of PH, right ventricular function and central hemodynamic health in 
individuals with severe lung disease (39).  
Although feasible; there are several limitations to invasive heart 
catheterization, especially during exercise, in healthy subjects and patients with 
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CF (40). Catheterization must be performed by a cardiologist and specialized 
groups of nurses which increases the cost greatly. The fluoroscopy used to 
insure proper placement of the catheter exposes the subject to radiation and, 
therefore, must be used sparingly to minimize the exposure risk. The measure 
also requires several pieces of specialized equipment including a supine cycle 
ergometer. This specialized bike allows the subject to peddle at increasing 
workloads while laying supine, similar to a bed with pedals at the foot. When 
exercise commences, and as work load increases, it is difficult to maintain the 
position of the catheter and to ensure the measures are being maintained 
properly becomes question. Beyond simple equipment limitations, the supine 
cycle ergometer has an important limitation in that it places the heart and lungs in 
an unnatural exercise position that artificially enhances venous return and 
influences pulmonary capillary recruitment. Other non-invasive measures have 
shown promise in estimating measures obtained via right heart catheterization 
but are not without limitations.  
 
Echocardiography has been utilized for the assessment of both left and 
right heart function as well as hemodynamic variables and pressure assessments 
in CF (16, 21), It has been shown to be useful in the examination of ventricular 
morphology, most notably right ventricular enlargement and hypertrophy (16, 23). 
Echocardiography has been used extensively in the assessment of PH, right 
ventricular free-wall thickness, and limitations in EF, all of which are useful in the 
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determination of the severity and progression of disease (12, 23, 33). 
Echocardiograms have become a routine part of standard patient evaluation 
clinically, due to widespread availability and non-invasive nature of the measures 
obtained (33). 
 
Despite its utility, echocardiography has limitations and is largely 
unreliable for several reasons. Echocardiography requires highly trained 
personnel, even in healthy subjects, and the level of training needed is even 
greater for this assessment in patients with CF; specifically, technicians need to 
have considerable experience with the disease for accurate echocardiography 
(23). Due to air trapping in patients with CF the pulmonary valve may be difficult 
or even impossible to visualize. This issue of physiologic vision is problematic in 
CF patients as estimates of pressure, flow and size require multiple vantage 
points that may not be available. It has been shown that the most severely ill 
patients that may benefit most from echocardiographic assessment have the 
highest failure rate with this method (23). Similarly, there have been high failure 
rates across the board among studies utilizing echocardiography in CF. In one 
such study it was not possible to measure pulmonary artery pressure in one third 
of their subjects (12). The same was found in another where the pulmonic valve 
was not visible in one third of the subjects imaged (23). In (33) only 65% of 
subjects had satisfactory examinations and in 13% of subjects in (12) 
echocardiographic assessment was not possible (12, 33). The shortcomings in 
  18 
physiologic vision are present in echocardiography when the subject is in optimal 
position and completely still. Echocardiography provides no valuable information 
during exercise (39). Pressure and hemodynamic adaptation to increasing 
workload may provide beneficial insight into the functional capacity and disease 
severity for patients with CF (16, 39). However, the probe used in 
echocardiography relies on stillness and a steady hand to capture relevant 
images for proper calculations. 
 
Emerging Technique for the Assessment of Cardiopulmonary Vascular 
Function; Pulmonary Capacitance 
 
Regardless of limitations, the need for estimating central hemodynamics is 
of the utmost importance in the proper assessment of cardiovascular function 
and disease progression. Pulmonary hemodynamics has a critical role and is of 
great clinical interest in various cardiac conditions such as right ventricular 
performance, congenital heart disease, cardiomyopathies and PH (39). Non-
invasive measures of pulmonary gas exchange at rest and during exercise may 
be useful in elucidating altered pulmonary vascular pressures in patients with and 
without PH, including end-tidal CO2 (PETCO2), and ventilatory efficiency (VE/VCO2) 
(17). Another common measure used to assess pulmonary hemodynamics is 
pulmonary vascular resistance (PVR) which has been shown to reflect small 
vessel resistance and pulmonary vascular cross-sectional area (39). A measure 
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that may assess medium and large pulmonary circulation, or account for pulsatile 
adaptation, is needed. Pulmonary capacitance has been associated with right 
ventricular work and assessment of clinical outcomes in COPD, PH and 
congestive HF (33, 35, 37, 38, 40). Pulmonary capacitance is expressed by the 
change in volume of blood to the change in pressure within the vessel (17, 39, 
41). 
 
PVCAP = Stroke Volume / Pulmonary Artery Pressure 
 
The distensability of the large and medium pulmonary arteries during right 
ventricular ejection is an important determinant of right ventricular work (16). 
Pulmonary capacitance may be an important factor and assessment tool 
influencing and predicting right ventricular function. Until recently, PVCAP has 
necessitated invasive right heart catheterization to directly assess PVCAP via 
pulmonary artery pulse pressure and SV (39). The aforementioned 
echocardiogram has also shown promise in non-invasive assessment of PVCAP; 
yet again this technique has been unreliable, at times, and can only be 
performed at rest (16, 39). Venuta et al clearly states that “no current test is 
universally applicable (for assessing CF severity) in fact, even spirometry might 
well depict the status of one patient and in other cases may not determine a rapid 
fatal outcome” (16). It has been suggested that it be possible to estimate PVCAP 
using non-invasive pulmonary gas exchange surrogates (17, 38). Oxygen pulse 
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(O2 pulse) which is a correction for O2 uptake for HR has correlated well with the 
SV response to exercise. While either SV or O2 pulse is representative of blood 
volume coming from the heart; End- tidal CO2 is thought to be a surrogate for 
pulmonary vascular pressure as there is a widening of the pulmonary arterials to 
differences in PETCO2 providing presumably a significant limitation in forward flow 
of blood through the pulmonary vasculature. This alteration is not attenuated 
during exercise and is specific to the pulmonary arterial circulation as the 
alteration is secondary to the increase in left atrial and pulmonary venous 
pressure. (17, 38). End-tidal CO2 has been shown to be sensitive enough to 
discriminate between differing severities within PH patients (38). Thus, this gas 
exchange estimate of pulmonary capacitance (GXCAP) is expressed as: 
 
GXCAP (mL / BEAT ∙ mmHg) = Stroke Volume (mL) ∙ PETCO2 (mmHg) 
 
Gas exchange estimate of pulmonary capacitance has been shown to be 
useful in HF, PH and healthy subjects (17, 28, 38, 42). The method has also 
been shown to correlate well with the gold standard of invasive heart 
catheterization (17). Unlike echocardiography this methodology would allow for 
continuous measures at rest and throughout peak exercise allowing for 
differential assessment. However this method has not yet been elucidated in CF 
at any stage in the disease. 
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Thus, the aim of the present study was first to determine the effects of 
exercise on GXCAP when compared to healthy subjects. Secondly, to ascertain 
whether a difference in GXCAP between healthy and CF subjects remains when 
workload is matched to control for SV, which seems to weigh heavily into the 
equation for GXCAP and is lower in patients with CF due to specific cardiac 
abnormalities.  
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CHAPTER 3. METHODOLOGY 
 
 
 
 
 
 
 
 
 
  23 
Study Population 
 
Data were collected at the University of Arizona and the study protocol 
was reviewed and approved by the University of Arizona Institutional Review 
Board (IRB). Additionally, the procedures followed in the study adhered to the 
University of Arizona’s IRB, the declaration of Helsinki and the Health Insurance 
Portability and Accountability Act (HIPAA) guidelines. All subjects provided 
signed informed written consent prior to the initiation of the study protocol. 
 
Seventeen mild to moderate CF patients, confirmed by a positive chloride 
sweat test (≥ 60 mmol/l Cl-) were recruited through the University of Arizona 
respiratory Center and its affiliated CF Clinic. Seventeen matched control 
subjects were recruited via advertising posted at the University of Arizona 
campus, and by word of mouth. Subjects were matched for age, gender, height, 
weight and BMI (Table 1. Subject Demographics). Patients with CF were 
excluded if they exhibited a FEV1 ≤40% predicted for their age, height, weight 
and gender, had experienced a pulmonary exacerbation within the last two 
weeks or a pulmonary hemorrhage in the six months prior to study (with a 
hemorrhage resulting in 50 cc of blood sputum). Subjects were also excluded if 
they were currently taking antibiotics or experimental drugs related to CF; these 
exclusion criteria ensured that CF patients within the study were clinically stable.  
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A urine-based pregnancy test was completed for female participants when 
applicable. 
 
Population Subset  
 
As a secondary study, a subset of the original subjects with CF were 
matched for similar workload and SV with healthy subjects. Matching these 
subjects resulted in 13 healthy normal control subjects and 9 CF patients. 
 
Measurements 
 
Rest 
Upon arrival to the laboratory height and weight were obtained using a 
standard stadiometer and electronic scale. Body Mass Index (BMI) was 
calculated as weight in kilograms divided by height in meters squared. Subjects 
were than outfitted with a 12-lead electrocardiogram (EKG) to monitor heart rate 
and rhythm (Marquette Electronics, Milwaukee, WI). Subjects then completed a 
full pulmonary function test (PFT) in accordance with American Thoracic Society 
(ATS) standards. From this maneuver it was possible to assess forced vital 
capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC, and 
forced expiratory flow at 25 to 75% of maximal effort (FEF25-75). Prediction 
estimates for pulmonary function measures were calculated per subject from 
NHANES III equations (43).  
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Cardiac output was assessed utilizing the acetylene rebreathe method 
and SV was determined by dividing the measured Q by HR assessed via 12-lead 
EKG. The rebreathe technique involves the subject breathing through a 
mouthpiece attached to a non-rebreathing Y-valve via a pneumotachograph 
(Hans Rudolph, KC, MO). The Y-valve inspiration port is controlled by a 
pneumatic switching valve allowing for instantaneous conversion from breathing 
room air and re-breathing in a 5-liter anesthesia bag containing 0.7% C2H2, 9% 
helium, 0.03% carbon monoxide (C18O) and balance nitrogen. Slope of the 
disappearance curve was calculated over ten breaths at rest and eight breaths 
during exercise to allow better toleration for the rebreathe method during 
exercise. Gases and inspiratory and expiratory flows were analyzed using a 
metabolic cart (Medical Graphics, St. Paul, MN) interfaced with a Perkins Elmer 
MGA-1100 mass spectrometer (Wesley, MN) for determination of gas 
concentration. 
 
Exercise 
 
All exercise testing took place on the same upright cycle ergometer 
(Corival Lode, The Netherlands). A subject specific testing protocol was utilized 
based on the type and intensity of the subject’s self-reported normal physical 
activity regiment as well as their body size. The initial workload also served as 
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the amount of work increased during each progressive stage of the exercise 
testing protocol. Subjects were asked to maintain a pedal rate between 60 and 
80 RPM. Workload was recorded throughout yielding watts (W), peak power, and 
allowing the percentage of max watts to be calculated from predicted equations. 
Failing to maintain a pedal rate of 60-80 RPM was a determinate of exhaustion. 
Other criterion for termination of the exercise test were a rate of perceived 
exertion (RPE) greater than 18 and a respiratory exchange ratio greater than 
1.15. When two of these criteria were met or the subject requested to stop the 
test was concluded. 
 
Statistical Analysis 
 
SPSS version 21.0 (SPSS, Chicago, IL, USA) was used for all statistical 
analyses. Results are expressed as mean + standard error of the mean (SEM). 
An independent sample t-test was used to compare subject demographic 
characteristics. Independent sample t-test was also used to describe differences 
between resting and exercise measures as well as differences between control 
and experimental groups. Correlations were performed to allow interpretation of 
strength of GXCAP to its component variables, SV and PETCO2. An alpha value of 
0.05 was used to signify statistical significance. GXCAP was calculated by the 
product of the average SV at the particular stage and the PETCO2 among the 
same. 
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Subject Characteristics 
 
 Healthy control and CF subjects were well matched within the study for all 
parameters other than lung function and exercise capacity, which were 
anticipated to be lower in CF. Seventeen control subjects and 19 CF subjects 
completed the study. There were no statistically significant anthropometric 
differences between the CF patients and healthy control subjects (Table 1). 
  
To determine the weight of SV and to evaluate its impact and influence on 
GXCAP, a population subset 13 healthy and 9 CF subjects were matched for 
exercise workload and SV. Healthy subjects again were well matched to CF 
subjects; age, height, weight and BMI. Cystic fibrosis subjects were not 
significantly different from the healthy controls with age, height, weight or BMI 
(Table 2).  
 
Pulmonary Function 
 
 As would be expected, control subjects demonstrated greater values in all 
pulmonary function measures with the exception of FVC% (table 1). 
 
Within the matched subjects there was no significant difference between 
healthy and CF in FVC or FEF25-75 percent predicted (p > 0.05). There was 
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however a significant difference in FEV1 percentage between heathy subjects 
and CF patients respectively (Table 2).  
 
Hemodynamics 
 
At rest; SV was higher in healthy subjects compared to CF patients. GXCAP 
was also higher in healthy subjects when compared to CF (p<0.05). However, 
PETCO2 remained unchanged between the two study groups (Table 3). 
 
During peak exercise, healthy subjects reached a higher absolute 
intensity. When absolute workload was expressed as a percentage of maximum 
however, there was no significant difference between healthy and CF (Table 1). 
Stroke volume and GXCAP increased in both healthy and CF from rest to peak 
exercise but remained significantly higher in healthy subjects when compared to 
CF at peak workloads (SV = 108 ± 5 vs. 84 ± 6 ml, GXCAP = 40 ± 3 vs. 29 ± 2, for 
healthy and CF, respectively (p<0.05) (Figure 1, 2). As in rest, at peak there was 
no significant difference in healthy and CF groups in PETCO2 (34±1 and 35±1 
respectively) (Figure 4). There was a strong positive correlation in both heathy 
and CF subjects between SV and GXCAP (R
2 of .86 for healthy and .89 for CF, 
p<0.05) (Figure 3).  
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 Within the population subset in which we sought to match SV there was a 
significant difference in absolute workload (Watts=72±6 vs. 90±4W CF and 
healthy subjects, respectively) but no difference in relative workload expressed 
as percentage of max wattage 63±4 %MaxW for CF and 66±5 %MaxW for their 
healthy counterparts (Figure 5). There was also no difference in Q or SV when 
CF and heathy subjects were matched respectively (Q 11±1 vs. 13±1L/min), or 
SV (89±4 vs. 90±4ml/beat) (Figure 6). Interestingly, when matched for SV, the 
previous difference in GXCAP between the groups was abolished (GXCAP for the 
healthy subjects =32±2  and CF subjects = 32±2 mL/BEAT ∙ min, Figure 6). 
PETCO2 remained similar between CF and healthy subjects when matched (PETCO2  
36±1 and  35±1mmHg). 
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CHAPTER 5. DISCUSSION 
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The degree to which pulmonary vascular dysfunction occurs at rest and 
during exercise in CF remains unclear. The aim of the present study was to 
ascertain differences in pulmonary vascular distensability using non-invasive 
inert gas-exchange methodology. To accomplish this goal this study utilized well-
matched CF and healthy control subjects to understand differences in PVCAP 
associated with CF.  Subjects shared basic anthropometric characteristics such 
as height, weight, and BMI. Both groups were also well matched in absolute and 
relative oxygen consumption as well as measures of pulmonary function at rest. 
Percent predicted values for CF subjects on pulmonary function maneuvers 
based on their height; weight and gender were relatively high; 83 percent 
predicted for FVC and 72 percent predicted for FEV1. This indicates that CF 
patients within the study population were generally healthy compared to similar 
studies (3, 4, 12, 14, 16, 27). We found that patients with CF had a lower GXCAP, 
when compared to healthy subjects, but that these differences were abolished in 
a subset of the population performing work that was matched for SV. These 
results suggest that the non-invasive GXCAP estimate may not be accurate in CF, 
due to the heavy reliance on SV.  
 
Pulmonary capacitance is a measure of the dispensability of the 
pulmonary arteries during right ventricular ejection and has been elucidated as 
an important metric in determining right ventricular work (17, 39, 41). The non-
invasive measure used within this study has already been shown to be a 
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surrogate for PVCAP, correlating well with direct measures within the 
catheterization laboratory in healthy subjects and patients with HF (17). Recently 
it has been suggested the PVCAP is associated with right ventricular work and a 
better predictor of clinical outcomes than that of more established methods. 
Pulmonary capacitance has also been shown to correlate higher than PVR, 
pulmonary wedge pressure, and pulmonary artery pressure in predicting negative 
clinical outcomes in HF and PH (17, 39, 41). Pulmonary capacitances, as well as 
other central hemodynamic measures have been described previously in CF 
patients awaiting lung transplant or within the end-stages of the disease; 
however, little work has been accomplished in young, relatively healthy, stable 
CF (5, 23, 26). Similarly the same technique has been used to evaluate an 
estimate of PVCAP within other diseased populations, such as PH and HF, but the 
present study is the first known use of this methodology in CF (17, 38). Within 
these other diseased populations the gas exchange estimate for pulmonary 
capacitance, GXCAP, has been shown to be sensitive enough to detect increases 
in this measure due to exercise as well as differentiate between disease 
severities. The GXCAP measure may prove useful in future diagnosis as well as 
ascertaining disease progression and severity within study populations where 
central hemodynamic dysfunction occurs, however this did not hold true within 
our study population (17, 38). The ability of this surrogate measure to assess and 
differentiate disease severity within HF and PH, but not in CF, may be due to the 
preservation of EF within the CF patients (18, 21, 30, 33). Ejection fraction is the 
  34 
quotient of blood ejected from the left ventricle during systole to the amount of 
blood left in the ventricle during diastole (45). Although there appears to be a 
reduction in SV among CF patients within this study, there may be a preservation 
of EF in the CF subjects which has been shown previously when compared to 
PH (30, 33).  
 
Gas exchange estimate of pulmonary capacitance was utilized to assess 
cardiopulmonary hemodynamics at rest to peak exercise. This provides dynamic 
information not permitted with methods such as echocardiography, where 
exercise is an impossibility due to the need of a steady hand and a motionless 
patient. Exercise is also not well tolerated in methods such as the direct Fick or 
thermodilution, as invasive heart catheterization and multiple venous and arterial 
lines make exercise cumbersome and patients uneasy. 
 
Initially, within the entire pool of subjects, there was a significant difference 
in SV between CF patients and healthy subjects at rest and at peak exercise. 
This has been described elsewhere within the research and is likely due to 
CFTR-specific effects on cardiac contractility (8, 21, 30). It was also evident that 
GXCAP was significantly lower in patients with CF compared to their healthy 
matched counterparts. There was however, no significant difference in PETCO2 
leading to the assumption that this difference in GXCAP was driven primarily by 
differences in SV. This offers evidence that there may be weaknesses within the 
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technique and that it may not provide accurate results in patients with CF. It has 
been suggested previously that PETCO2 may provide insight into pulmonary 
vascular constriction or, inversely, dilation, and this provides the rationale behind 
the use of PETCO2 as an estimate of pulmonary vascular conductance (17, 38). 
PETCO2 has been shown here to be a poor predictor of pulmonary vascular 
pressure as well as shown no significant difference from peak to rest between 
healthy and CF subjects as well as provide no correlation to GXCAP.  
 
Despite our finding that there was no difference in GXCAP it is clear that 
chronic inflammation leads to the remodeling of the pulmonary tissue, most 
notably the small blood vessels of the lung (4, 14) highlighting the need for more 
sensitive measures of pulmonary vascular function in patients with CF. The cycle 
of chronic inflammation coupled with infection, parenchymal fibrosis and 
bronchiectasis lead to the inevitable destruction of the lung tissue. Destruction 
and subsequent vascular remodeling is also compounded by hypoxic pulmonary 
vasoconstriction leading to increasing vascular resistance and ultimately 
irreversible PH (1, 3, 12, 38). However, why the venous portion of the pulmonary 
vasculature seems immune to this remodeling and why some patients develop 
PH and others do not have yet to be explained. Studies in other disease states 
with progressive respiratory failure have demonstrated that right HF is inevitable; 
this too may be true of CF as the patient’s life expectancy lengthens. Although 
not a focus of this study, previous work has shown an abnormal hemodynamic 
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response apparent in CF during exercise, as well as an increase in mean 
pulmonary artery pressure and decreased EF (3, 18). 
 
The GXCAP estimate of pulmonary vascular pressure assumes that the 
pulmonary vasculature dilates in response to increases in SV. However, in 
patients who experience chronic hypoxic pulmonary vasoconstriction, there may 
be an opposing mechanistic narrowing of the pulmonary vascular bed in 
response to hypoxia. Therefore, the GXCAP equation may not be reliable in CF as 
the equation may be confounded by this vasoconstriction. The need for a more 
comprehensive equation may be warranted that accounts for variables. An 
equation that accounts for Q, SV and perhaps diffusion for carbon dioxide to 
ascertain membrane conductance (Dm) and pulmonary capillary blood volume 
(Vc). 
 
Potential limitations of the following study are due to the size and disease 
severity of our CF population. CF subjects were on the healthy end of the 
disease spectrum representing a wide variety of disease severity; that coupled 
with the small sample size left no room for stratification of the disease (i.e. mild, 
moderate and severe disease states). It has been shown that central 
hemodynamic dysfunction may only be apparent in end stage CF, warranting 
further study into central hemodynamic changes in different stages of the disease 
progression. 
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CHAPTER 6. CONCLUSION 
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This is the first known study of healthy, stable, CF central hemodynamics 
utilizing inert gas exchange to estimate pulmonary capacitance. We initially found 
that GXCAP was reduced at rest and at peak exercise; it was however evident that 
this difference was driven by differences in SV between healthy subjects and CF 
patients. We sought to match subjects and patients via workload and therefore 
SV; when matched the apparent difference in GXCAP was ameliorated. The 
GXCAP equation was found to poorly predict pulmonary vascular pressure, 
leading to the realization that there may be better predictors of central 
hemodynamic dysfunction. Weakness in the equation not previously identified in 
other diseased populations may be elucidated in CF. Future work is required in 
developing simplistic, reliable, valid and non-invasive clinical measures for the 
assessment for PVCAP. Work is also warranted to shed light on cardiac and 
pulmonary vascular dysfunction in multiple stages of disease progression in CF 
as patients experience increased longevity.  
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Table 1. Demographic Characteristics: Unmatched 
  Rest   Peak   
  Healthy CF Healthy CF 
Sample Size 17 19 
 
  
Age (yrs.) 22 ± .585 22 ± 1.7 
 
  
Height (cm) 171 ± 2 167 ± 2 
 
  
Body Mass (kg) 68 ± 2 63 ± 4 
 
  
BMI (kg∙m2) 23 ± .5 23 ± 1     
VO2
 (mL/Kg/min) 6 ± 2 6 ± 2 35 ± 11 24 ± 9* 
Peak Power (W) 
  
185 ± 65 101 ± 35 
% of Max (W)     96 ± 31 52 ± 15 
FVC (%) 93 ± 3 83 ± 5 4 ± 1 3 ± 1 
FEV1 (%) 89 ± 2 72 ± 6 4 ± 1 3 ± 1 
FEV1/FVC .81 ± .02 .72 ± .03* 1 ± .07 1 ± .09 
(mean ± standard error of the mean) 
BMI (body mass index), VO2 (oxygen consumption), FVC (forced vital capacity), 
FEV1 (forced expiratory volume in one second).  
* demonstrates significance differences between healthy and CF subjects at α< 
.05  
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Table 2. Demographic Characteristics: Matched  
  Healthy CF 
Sample Size 13 9 
Age (yrs.) 28 ± 10 22 ± 9 
Height (cm) 168 ± 10 170 ± 7 
Body Mass (kg) 70 ± 16 66 ± 17 
BMI (kg∙m2) 25 ± 5 23 ± 4 
FEV1 (%) 93 ± 11 85 ± 19 * 
FVC % Predicted 92 ± 8 95 ± 13 
FEF25-75 % Predicted 94 ± 17 68 ± 31 
(mean ± standard error of the mean) 
FEF25-75 (forced expiratory at 25-75% of volume) 
* demonstrates significance differences between healthy and CF subjects at α< 
.05 
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Table 3. Exercise Performance: Matched 
  Healthy CF 
Sample Size 13 9 
Work (W) 90 ± 16 72 ± 18 * 
% of Max (W) 66 ± 18 63 ± 13 
VO2
 (L/min) 5 ± 2 7 ± 2 
VO2
 (ml/kg/min) 23 ± 6 19 ± 3 
VO2 % Predicted 83 ± 22  53 ± 27 
VCO2 (mL) 1276 ± 345 1227 ± 454  
SV (mL) 90 ± 4 89 ± 4 
PETCO2 (mmHg) 36 ± 3 34 ± 3 
GXCAP (mL/BEAT ∙ mmHg) 18 ± 5 21 ± 7 
(mean ± standard error of the mean)\ 
W (watts) 
* demonstrates significance differences between healthy and CF subjects at α< 
.05 
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Figure 1. Stroke Volume at Rest & Peak Exercise: Unmatched 
 
Figure 1 Shows similar decrease in SV in CF as well compared to healthy 
counterparts; significant at α=.05 
* demonstrates significance differences between healthy and CF subjects at α< 
.05 
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Figure 2. GXCAP at Rest & Peak Exercise: Unmatched 
 
Figure 2 Shows decreased GXCAP in CF compared to healthy subjects. 
* demonstrates significance differences between healthy and CF subjects at α< 
.05 
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Figure 3. PETCO2 at Rest & Peak Exercise: Unmatched 
 
There was no significant difference between Healthy and CF PETCO2 (30 and 30 
mmHg) at α=.05. 
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Figure 4. Healthy and CF SV to GXCAP Correlations: Unmatched 
 
Figure 3: SV and GXCAP were highly correlated at an R
2 of .89 and .86 for CF and 
healthy subjects respectively. 
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Figure 5. Absolute & Relative Workload for Healthy & CF: Matched 
 
  
 
 
 
 
 
 
 
 
 
 
 
When matched for relative workload (~65% peak workload), CF subjects worked 
at a significantly lower absolute workload. 
* demonstrates significance differences between healthy and CF subjects at α< 
.05 
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Figure 6. Stroke Volume & GXCAP: Matched 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When matched for relative workload and therefore stroke volume, GXCAP was 
statistically similar between healthy and CF subjects.  
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